Email Alert | RSS    帮助

中国防痨杂志 ›› 2005, Vol. 27 ›› Issue (1): 26-28.

• 论著 • 上一篇    下一篇

含药凝胶介入治疗耐多药空洞肺结核的初步临床研究

王安生;王巍;林明贵;陈红兵;李素梅;   

  1. 解放军309医院全军结核病中心 北京 100091;
  • 出版日期:2005-01-10 发布日期:2005-11-03

The clinical study on treatment of multi-drug resistance pulmonary tuberculosis with containing drug gelatin by bronchofiberscoope

Wang Anseng,Wang wei,Ling Minggui,et al.   

  1. Tuberculosis Center of PLA,309th Hospital of PLA,Beijing 100091,China
  • Online:2005-01-10 Published:2005-11-03

摘要: 目的 评价经纤支镜灌注含药凝胶治疗耐多药肺结核的临床疗效和安全性。方法 治疗组用纤支镜灌注含药凝胶治疗和抗结核药物治疗,对照组用抗结核药物治疗。观察治疗效果。结果治疗 6月后,治疗组痰菌阴转率 73.1%,病灶治疗有效率 85.4%,空洞治疗有效率 81%,明显高于对照组 51.3%,56.7%和 51.4%(P<0.05 ),治疗组痰菌阴转时间 36.3d,比对照组 61.8d明显缩短(P<0.01 )。治疗组无严重不良反应。结论 经纤支镜含药凝胶灌注治疗耐多药肺结核疗效优于单纯药物治疗,是治疗耐多药肺结核病的一种有效、安全的方法。

关键词: 结核,肺/药物疗法, 结核,抗多种药物性

Abstract: Objective To evaluate the clinical treatment outcome and safety of the treatment approaches for multi-drug resistance pulmonary tuberculosis with containing drug gelatin by fiberbronchoscope.Methods The matients were treated with containing drug gelatin by bronchofiberscope and antituberculosis treatment in experiment group;the patients were treated only by antituberculosis treatment in control group.The clinical treatment outcome were observed.Results At the end of six months therapy,the sputum conversion rate was 73.1%,foci marked absorption rate was 85.4%,and cavity curative effect rate was 81% in experiment group,all of which were higher than that of the controls (51.3%, 56.7% and 51.4%)(P<0.05).The duration of sputum conversion time was 36.3d in experiment group,it was shorter than that of the controls (61.8 d),(P<0.01).There were not severe adverse reaction observed in experiment group.Conclusion The efficiency of the containing drug gelatin by fiberbronchoscoope combined with routine antituberculosis treatment is better than the routine antituberculosis treatment only.The treatment approaches were effective and safe in treatment of multi-drug resistance pulmonary tuberculosis.

Key words: Pulmonary tuberculosis/drug therapy, Multidrug-resistant